非诺贝特与高甘油三酯血症病人基质金属蛋白酶2活性

Fenofibrate and levels of serum matrix metalloproteinase-2 in patients with hypertriglyceridemia

目的观察高甘油三酯血症病人血管内皮依赖性舒张功能和血清基质金属蛋白酶2(Matrixmetalloproteinase-2,MMP-2)含量及非诺贝特的影响。方法高甘油三酯(triglyceride,TG)血症病人30例,TG超过1.7mmol/L;健康体检者30例,观察血管内皮依赖性舒张功能。用酶联免疫吸附试验检测血清中MMP-2含量,观察非诺贝特口服剂量200mg/d治疗8周对上述指标的影响。结果高甘油三酯血症病人血管内皮依赖性舒张功能及血清中肿瘤坏死因子-α,MMP-2的浓度明显高于健康人(P<0.01);用非诺贝特治疗后,病人血清中肿瘤坏死因子-α,MMP-2浓度较前下降,内皮依赖性舒张功能高于治疗前(P<0.01)。结论高甘油三酯血症病人存在血管内皮舒张功能障碍;非诺贝特能显著改善高甘油三酯血症病人血管内皮依赖性舒张功能,其内皮保护作用可能与降低血清中MMP-2浓度有关。

Objectives To investigate endothelium-dependent flow-mediated dilatation(FMD) and the serum level of matrix metalloproteinase-2 (MMP-2) in hypertriglyceridemia patients and to study effect of fenofibrate. Methods FMD and serum concentrations of MMP-2 were determined in 30 patients with hypertriglyceridemia and 30 normal controls. Patients with hypertriglyceridemia were treated with fenofibrate. After 8 weeks, transformations of FMD and serum levels of MMP-2 were determined. Results Patients with hypertriglyceridemia caused a marked decrease in endothelium-dependent flow-mediated dilatation (FMD). Compared with control, the serum levels of MMP-2 and tumor necrosis factor-α(TNF-α) were markedly increased in patients. After treatment with fenofibrate for 8 weeks, FMD of the patients were improved. Treated with fenofibrate significantly reduced the elevated levels of MMP-2 and TNF-α. Conclusions These results suggest that patients with hypertriglyceridemia have vascular endothelium dysfunction and the management of fenofibrate can improve the patients' FMD. The protective effect of fenofibrate on endothelial cells maybe relates to reduction of serum MMP-2 level.